Get the Stockscreener App
55.33
1.66%
-1.015
Crispr Therapeutics Ag stock is traded at $55.33, with a volume of 840.22K.
It is down -1.66% in the last 24 hours and up +8.23% over the past month.
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
See More
Previous Close:
$56.34
Open:
$56.35
24h Volume:
840.22K
Relative Volume:
0.27
Market Cap:
$4.78B
Revenue:
$170.10M
Net Income/Loss:
$-239.59M
P/E Ratio:
-19.76
EPS:
-2.8
Net Cash Flow:
$-191.20M
1W Performance:
-1.52%
1M Performance:
+8.23%
6M Performance:
+39.52%
1Y Performance:
+17.21%
1-Day Range:
$54.84
$56.80
1-Week Range:
$52.50
$59.89
52-Week Range:
$30.04
$71.13
Crispr Therapeutics Ag Stock (CRSP) Company Profile
Name
Crispr Therapeutics Ag
Sector
Industry
Phone
(617) 315-4600
Address
BAARERSTRASSE 14, ZUG
Compare CRSP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CRSP
Crispr Therapeutics Ag
|
55.30 | 5.06B | 170.10M | -239.59M | -191.20M | -2.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
383.97 | 96.11B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.42 | 60.40B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
429.95 | 54.91B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
670.26 | 41.30B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
295.12 | 33.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Crispr Therapeutics Ag Stock (CRSP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-14-25 | Upgrade | Evercore ISI | In-line → Outperform |
| Feb-12-25 | Upgrade | TD Cowen | Sell → Hold |
| Feb-03-25 | Initiated | H.C. Wainwright | Buy |
| Aug-06-24 | Reiterated | Needham | Buy |
| Aug-02-24 | Initiated | Rodman & Renshaw | Buy |
| Jun-28-24 | Resumed | Guggenheim | Neutral |
| Feb-15-24 | Initiated | Wolfe Research | Peer Perform |
| Dec-11-23 | Downgrade | TD Cowen | Market Perform → Underperform |
| Oct-17-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Sep-27-23 | Initiated | Mizuho | Buy |
| Aug-17-23 | Upgrade | Citigroup | Neutral → Buy |
| May-30-23 | Initiated | William Blair | Outperform |
| Apr-13-23 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-21-23 | Initiated | Bernstein | Mkt Perform |
| Mar-17-23 | Initiated | Bryan Garnier | Buy |
| Mar-07-23 | Initiated | Robert W. Baird | Neutral |
| Oct-11-22 | Initiated | Morgan Stanley | Underweight |
| Aug-09-22 | Downgrade | Barclays | Overweight → Equal Weight |
| Jun-23-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Jun-17-22 | Initiated | BMO Capital Markets | Outperform |
| Apr-28-22 | Initiated | Credit Suisse | Neutral |
| Dec-07-21 | Initiated | Cowen | Market Perform |
| Oct-19-21 | Initiated | SVB Leerink | Outperform |
| Jun-14-21 | Upgrade | Citigroup | Sell → Neutral |
| Apr-21-21 | Upgrade | Jefferies | Hold → Buy |
| Mar-04-21 | Initiated | JMP Securities | Mkt Outperform |
| Dec-10-20 | Reiterated | Chardan Capital Markets | Buy |
| Dec-10-20 | Downgrade | Jefferies | Buy → Hold |
| Dec-10-20 | Reiterated | Needham | Buy |
| Dec-07-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Oct-23-20 | Initiated | RBC Capital Mkts | Sector Perform |
| Oct-05-20 | Initiated | BofA Securities | Buy |
| Jul-28-20 | Reiterated | Needham | Buy |
| Jul-14-20 | Initiated | SunTrust | Buy |
| Jun-15-20 | Reiterated | Canaccord Genuity | Buy |
| Mar-05-20 | Initiated | Stifel | Hold |
| Feb-03-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Nov-19-19 | Upgrade | William Blair | Mkt Perform → Outperform |
| Nov-12-19 | Upgrade | Oppenheimer | Perform → Outperform |
| Aug-01-19 | Initiated | Jefferies | Buy |
| Jul-26-19 | Initiated | Canaccord Genuity | Buy |
| Jun-10-19 | Initiated | ROTH Capital | Buy |
| Apr-12-19 | Initiated | Evercore ISI | Outperform |
| Mar-14-19 | Initiated | William Blair | Mkt Perform |
| Jan-28-19 | Downgrade | Goldman | Buy → Neutral |
| Jan-22-19 | Downgrade | Citigroup | Neutral → Sell |
View All
Crispr Therapeutics Ag Stock (CRSP) Latest News
Brookline Capital Management Estimates CRSP Q3 Earnings - MarketBeat
Leerink Partnrs Has Pessimistic View of CRSP Q3 Earnings - MarketBeat
Crispr Therapeutics AG: Strong Sales Growth and Global Expansion Justify Buy Rating - TipRanks
FY2027 Earnings Estimate for CRSP Issued By Leerink Partnrs - MarketBeat
HC Wainwright Raises CRISPR Therapeutics (NASDAQ:CRSP) Price Target to $80.00 - MarketBeat
CRISPR Therapeutics stock price target raised to $80 by H.C. Wainwright - Investing.com Nigeria
Banque Cantonale Vaudoise Makes New Investment in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
Privium Fund Management B.V. Acquires 25,100 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
CRISPR Therapeutics' (CRSP) "Buy" Rating Reiterated at Chardan Capital - MarketBeat
CRISPR Therapeutics (NASDAQ:CRSP) Issues Quarterly Earnings Results, Beats Expectations By $0.18 EPS - MarketBeat
CRISPR Therapeutics (NASDAQ:CRSP) Shares Gap DownShould You Sell? - MarketBeat
CRSP Stock Down on Huge Q2 Loss, Focus on Increasing Casgevy Adoption - Zacks Investment Research
CRISPR Therapeutics (NASDAQ:CRSP) Price Target Raised to $42.00 at Royal Bank Of Canada - MarketBeat
Up 50% in 3 Months, Is This Stock Still a Buy? - The Motley Fool
Crispr Therapeutics AG: Strong Financial Foundation and Promising Pipeline Amidst Strategic Growth - TipRanks
IQ EQ FUND MANAGEMENT IRELAND Ltd Has $2.22 Million Stake in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
Crispr Therapeutics AG: Promising Growth and Expanding Pipeline Justify Buy Rating - TipRanks
Bayforest Capital Ltd Purchases Shares of 12,424 CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
CRISPR Therapeutics AG (CRSP) Reports Q2 Loss, Lags Revenue Estimates - MSN
CRISPR Therapeutics AG reports results for the quarter ended June 30Earnings Summary - TradingView
Crispr Therapeutics shares tumble after significant earnings miss By Investing.com - Investing.com Nigeria
Crispr Therapeutics shares tumble after significant earnings miss - Investing.com
Crispr Therapeutics earnings missed by $1.00, revenue fell short of estimates - Investing.com
CRISPR Therapeutics AG SEC 10-Q Report - TradingView
CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results - GlobeNewswire
Published on: 2025-08-04 01:34:11 - Jammu Links News
What analysts say about CRISPR Therapeutics AG stockCapitalize on market trends with confidence - Jammu Links News
What are CRISPR Therapeutics AG company’s key revenue driversCapitalize on fast-moving stock trends - Jammu Links News
What are the latest earnings results for CRISPR Therapeutics AGMaximize gains with data-driven stock picks - Jammu Links News
What is Zacks Research's Estimate for CRSP Q2 Earnings? - MarketBeat
When is CRISPR Therapeutics AG stock expected to show significant growthFree Trading Strategy Suggestions - Jammu Links News
What drives CRISPR Therapeutics AG stock priceAchieve consistent double-digit growth - Jammu Links News
Published on: 2025-08-03 05:26:58 - Jammu Links News
CRISPR Therapeutics (CRSP) Sees 47% Price Increase Over Last Quarter - simplywall.st
CRISPR Therapeutics AG (CRSP) Sees a More Significant Dip Than Broader Market: Some Facts to Know - MSN
Cerity Partners LLC Invests $216,000 in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
CRISPR Therapeutics (NASDAQ:CRSP) Stock Price Down 4.1%Here's What Happened - MarketBeat
Is CRISPR Therapeutics AG a growth stock or a value stockAdvanced Screener Ideas For Every Investor - Jammu Links News
Inspire Advisors LLC Invests $459,000 in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
Crispr Therapeutics shares rise 1.18% after-hours following Intellia Therapeutics' inducement grants announcement. - AInvest
How volatile is CRISPR Therapeutics AG stock compared to the marketAI Powered Review For 2025 - jammulinksnews.com
Is CRISPR Therapeutics AG stock overvalued or undervaluedStock Strategy Signals For Smart Trading - jammulinksnews.com
Published on: 2025-07-30 00:12:31 - beatles.ru
Should You Invest in CRISPR Therapeutics (CRSP) Based on Bullish Wall Street Views? - Yahoo Finance
CRISPR Therapeutics to Report Q2 Earnings: What's in the Cards? - MSN
CRISPR Therapeutics AG (NASDAQ:CRSP) is ARK Investment Management LLC's 10th Largest Position - MarketBeat
CRISPR Therapeutics AG (CRSP) May Report Negative Earnings: Know the Trend Ahead of Q2 Release - MSN
Crispr Therapeutics Ag Stock (CRSP) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.36%
1.76%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):